Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05975398

China Research for Severe Spontaneous Intracerebral Hemorrhage(CRISIH)

Background: Although emergency surgery may reduce mortality in patients with severe spontaneous intracerebral hemorrhage (SSICH), the effectiveness and safety of surgical treatment among SSICH patients receiving long-term oral antiplatelet therapy (LOAPT) remain unclear. The CRISIH registry was originally designed to evaluate the effect and safety of emergency surgery in SSICH patients receiving LOAPT and has subsequently continued as an ongoing multicenter registry of spontaneous intracerebral hemorrhage.

Methods: The CRISIH registry is an ongoing prospective, multicenter cohort registry conducted across participating clinical centers in China. The registry was initiated in November 2019 and is designed as a 10-year registry with continued recruitment and follow-up. Data from the initial five-year enrollment period are used for interim and secondary analyses, while recruitment and follow-up continue during the subsequent registry period. Clinical, radiological, surgical, laboratory, and follow-up information are collected using standardized case report forms. For the originally registered primary outcome, patients are followed until death or 6 months after the occurrence of primary hemorrhage; selected follow-up assessments and secondary analyses may extend beyond this period according to the registry protocol.

Study Design: The CRISIH registry was designed as a prospective, multicenter cohort registry of patients with spontaneous intracerebral hemorrhage. One originally registered comparative focus evaluates SSICH patients receiving LOAPT, comparing total mortality and survival outcomes between patients receiving emergency surgical treatment and those receiving conservative treatment. The safety of surgery is assessed by comparing postoperative hemorrhagic complications among operated patients with and without LOAPT. Based on the observed clinical characteristics and outcomes of patients receiving LOAPT, the registry also evaluates ischemic events after discontinuation of LOAPT and explores coagulation function assessment strategies in operated patients receiving LOAPT.

Objective: The CRISIH registry aims to prospectively evaluate clinical outcomes and management strategies in patients with spontaneous intracerebral hemorrhage. An originally registered focus of the registry is to assess the effectiveness and safety of emergency surgery among SSICH patients receiving LOAPT, thereby generating evidence to support future clinical management.

Secondary Analysis Update: The present update describes an interim secondary analysis of the ongoing CRISIH registry based on patients enrolled during the initial five-year period from November 2019 to December 2024. This analysis focuses on postoperative disorders of consciousness after surgery for spontaneous intracerebral hemorrhage, with consciousness status assessed at 30, 90, 180, and 365 days after surgery using the Coma Recovery Scale-Revised. This interim secondary analysis does not alter the ongoing registry design, recruitment status, or originally registered primary outcome.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Capital Medical University Affiliated Beijing Tiantan Hospital

Beijing, Beijing Municipality, China

Location status: Recruiting

Location contact

JUN WU, MD

CONTACT

[email protected]

+8613426322945

Shuo Wang, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older.
  • Spontaneous, nontraumatic intracerebral hemorrhage.
  • Treatment with surgical or conservative management according to clinical indications and routine clinical practice.
  • Written informed consent provided by the patient or legally authorized representative/family member.

Exclusion criteria

  • Patients had cerebrovascular diseases associated with hemorrhage, such as intracranial aneurysm, cerebrovascular malformation, or intracranial tumors.
  • Hemorrhagic transformation of cerebral infarction.
  • Hemorrhage caused by cerebral venous thrombosis.
  • Patients with severe coagulation disorder, such as hemophilia.
  • Patients with coagulation dysfunction caused by malignant tumor, hepatic insufficiency, renal dysfunction, thrombocytopenia, coagulation diseases, or related conditions.
  • Patients receiving other anticoagulation medications, including vitamin K antagonists or novel oral anticoagulants.
  • Patients who died before arrival at the hospital, on arrival at the hospital, or within a short period (6 hours) after admission.

Treatment and study plan

Emergency neurosurgery

Procedure

Surgical evacuation for intracerebral hemorrhage

Conservative treatment

Procedure

Standard treatment for intracerebral hemorrhage

Primary outcomes

  1. Total mortality

    Time frame: From admission to 6 months after the occurrence primary hemorrhage

Secondary outcomes

  1. Postoperative intracranial bleeding

    Time frame: Within one week after surgery

  2. Postoperative disorders of consciousness

    Time frame: 30, 90, 180, and 365 days after surgery

    Proportion of patients with postoperative disorders of consciousness after surgery for spontaneous intracerebral hemorrhage, assessed using the Coma Recovery Scale-Revised.

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Beijing Tiantan Hospital

Other

Collaborators

  • Anxi County Hospital
  • Beijing Anzhen Hospital
  • Beijing Chao Yang Hospital
  • Beijing Friendship Hospital
  • Beijing Pinggu District Hospital
  • Beijing Shuyi Hospital
  • Binzhou People's Hospital
  • Datong People's Hospital
  • Dezhou People's Hospital
  • First Affiliated Hospital of Fujian Medical University
  • Guangzhou Red Cross Hospital
  • Jincheng People's Hospital
  • Jingzhou Central Hospital
  • Jiuquan City People's Hospital
  • Qingyuan People's Hospital
  • Shijiazhuang Third Hospital
  • The First Affiliated Hospital of Zhengzhou University
  • Wuxi No. 2 People's Hospital
  • Xinyu People's Hospital
  • Zhoukou People's Hospital

Registry information

Important dates

Study start
2019
Primary completion
2029
Study completion
2030
First posted
Aug 3, 2023
Registry last updated
Jul 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.